Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCL

Swetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.

Related Keywords

Swetha Kambhampati ,Department Of Hematology Hematopoietic Cell Transplantation ,Division Of Lymphoma ,Hematopoietic Cell Transplantation ,Phase 2 Zuma Trial ,Relapsed Refractory Mantle Cell Lymphoma ,Brexucabtagene Autoleucel Tercartus Brexu Cel ,Cart Cell Therapy ,Real World Efficacy ,